TATTON trial – Savolitinib plus osimertinib in EGFR-mutated, MET-amplified NSCLC | Lecia Sequist

(4:49)

Dr. Oxnard on the Role of Osimertinib in the TATTON Trial for Lung Cancer

(1:26)

Dr. Sequist on Rationale for TATTON Trial in EGFR-Mutant Lung Cancer

(1:11)

TATTON trial – Exploring options for EGFR inhibitor-resistant NSCLC | Roy Herbst

(2:54)

TATTON: Phase 1b trial of AZD9291 for EGFR-mutant lung cancer

(4:50)

TATTON: Phase 1b trial of combination therapies with AZD9291 in EGFR-mutant lung cancer

(4:46)

TATTON: Updated results for patients with EGFR-mutant positive NSCLC

(9:25)

TATTON: Osimertinib plus savolitinib for patients with EGFR-mutant, MET-amplified NSCLC after pr...

(2:30)

Understanding, preventing, and delaying EGFR resistance in the era of Osimertinib

(20:18)

ACRP Clinical Trials Day Testimonial: Deb Tatton, Parexel

(41)

Dr. Ramalingam on the Use of Osimertinib in Clinical Trial and Real-World Settings

(1:45)

Understanding EGFR Resistance in Patients With MET-Amplified NSCLC

(2:2)

Osimertinib, the Standard for EGFR+ NSCLC

(6:6)

Abbi Tatton on Bloggers Covering Lewis 'Scooter' Libby Trial

(1:45)

Dr. Kate Tatton-Brown, \

(19:3)

Tatton Brown Rahman Syndrome (TBRS) Research

(3:47)

The FLAURA Trial in EGFR+ NSCLC

(1:59)

What is a clinical trial drug treatment protocol?

(1:28)

ENZAMET trial

(6:5)